Will newer tyrosine kinase inhibitors have an impact in AML?

Best Practice and Research: Clinical Haematology

Volumn 23, Issue 4, 2010, Pages 489-494

  Levis, Mark J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

AC220; Acute myeloid leukemia; AML; FLT3; Inhibitor; KW 2449; Lestaurtinib; Midostaurin; Sorafenib

Indexed keywords

AC 220; CD135 ANTIGEN; KW 2449; LESTAURTINIB; MIDOSTAURIN; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; DRUG HALF LIFE; DRUG POTENCY; GENE MUTATION; HUMAN; IC 50; MONOTHERAPY; PRIORITY JOURNAL; REVIEW;

CLINICAL TRIALS AS TOPIC; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROTEIN KINASE INHIBITORS;

EID: 78649931161     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2010.09.008     Document Type: Review

References (38)

1. M. Nakao, S. Yokota, and T. Iwai Internal tandem duplication of the flt3 gene found in acute myeloid leukemia Leukemia 10 1996 1911 1918
2. H. Kiyoi, M. Towatari, and S. Yokota Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product Leukemia 12 1998 1333 1337
3. P.D. Kottaridis, R.E. Gale, and M.E. Frew The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 98 2001 1752 1759
4. S.P. Whitman, K.J. Archer, and L. Feng Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study Cancer Res 61 2001 7233 7239
5. S. Schnittger, C. Schoch, and M. Dugas Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease Blood 100 2002 59 66
6. C. Thiede, C. Steudel, and B. Mohr Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 99 2002 4326 4335
7. M. Levis, and D. Small FLT3: ITDoes matter in leukemia Leukemia 17 2003 1738 1752
8. K.W. Pratz, and M.J. Levis Bench to bedside targeting of FLT3 in acute leukemia Curr Drug Targets 11 2010 781 789
9. D. Small, M. Levenstein, and E. Kim STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells Proc Natl Acad Sci U S A 91 1994 459 463
10. H. Kiyoi, T. Naoe, and Y. Nakano Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia Blood 93 1999 3074 3080
11. Y. Liu, and N.S. Gray Rational design of inhibitors that bind to inactive kinase conformations Nat Chem Biol 2 2006 358 364
12. M. Levis, and D. Small FLT3 tyrosine kinase inhibitors Int J Hematol 82 2005 100 107
13. M. Levis, P. Brown, and B.D. Smith Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors Blood 108 2006 3477 3483
14. B.D. Smith, M. Levis, and M. Beran Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia Blood 103 2004 3669 3676
15. S. Knapper, A.K. Burnett, and T. Littlewood A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy Blood 108 2006 3262 3270
16. K.W. Pratz, J. Cortes, and G.J. Roboz A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response Blood 113 2009 3938 3946
17. K.W. Pratz, E. Cho, and M.J. Levis A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias Leukemia 2010
18. F. Ravandi, J.E. Cortes, and D. Jones Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia J Clin Oncol 28 2010 1856 1862
19. M. Levis, J. Allebach, and K.F. Tse A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo Blood 99 2002 3885 3891
20. E. Weisberg, C. Boulton, and L.M. Kelly Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412 Cancer Cell 1 2002 433 443
21. S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis Cancer Res 64 2004 7099 7109
22. R.M. Stone, D.J. DeAngelo, and V. Klimek Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Blood 105 2005 54 60 (Pubitemid 40053063)
23. W. Zhang, M. Konopleva, and Y.X. Shi Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia J Natl Cancer Inst 100 2008 184 198
24. Y. Shiotsu, H. Kiyoi, and Y. Ishikawa KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation Blood 114 2009 1607 1617
25. P.P. Zarrinkar, R.N. Gunawardane, and M.D. Cramer AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) Blood 114 2009 2984 2992
26. D.J. Propper, A.C. McDonald, and A. Man Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C J Clin Oncol 19 2001 1485 1492
27. J.L. Marshall, H. Kindler, and J. Deeken Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor Invest New Drugs 23 2005 31 37
28. M.W. Karaman, S. Herrgard, and D.K. Treiber A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 2008 127 132
29. D.J. George, C.A. Dionne, and J. Jani Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555) Cancer Res 59 1999 2395 2401
30. M. Levis, B.D. Smith, and M. Beran A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition Blood 106 2005 121a
31. S. Knapper, A. Burnett, and R.K. Hills Lestaurtinib FLT3 Inhibitory Activity Is Modulated by Concomitant Azole Therapy and May Influence Relapse Risk Blood 114 2009 326a
32. R.M. Stone, T. Fischer, and R. Paquette Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Patients with AML Blood 106 2005 121a
33. V. Gupta-Abramson, A.B. Troxel, and A. Nellore Phase II trial of sorafenib in advanced thyroid cancer J Clin Oncol 26 2008 4714 4719
34. G.K. Abou-Alfa, L. Schwartz, and S. Ricci Phase II study of sorafenib in patients with advanced hepatocellular carcinoma J Clin Oncol 24 2006 4293 4300
35. S. Metzelder, Y. Wang, and E. Wollmer Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation Blood 113 2009 6567 6571
36. J. Winkler, D. Rech, and S. Kallert Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: A case report Leuk Res 34 2010 e270 e272
37. J. Cortes, J. Foran, and D. Ghirdaladze AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study Blood 114 2009 636
38. J. Cortes, J. Foran, and M. Devetten Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor Blood 110 2007 477a